Generation and characterization of adeno-associated virus producer cell lines for research and preclinical vector production

Human Gene Therapy Methods

Volumn 24, Issue 4, 2013, Pages 253-269

  Martin, John ^a   Frederick, Amy ^a   Luo, Yuxia ^a   Jackson, Robert ^a   Joubert, Michelle ^a   Sol, Bruce ^a   Poulin, Francis ^a   Pastor, Eric ^a   Armentano, Donna ^a   Wadsworth, Samuel ^a   Vincent, Karen ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALKALINE PHOSPHATASE PLACENTA ISOENZYME; CAPSID PROTEIN; HELICASE; PLASMID DNA; PLASMID VECTOR; VIRUS DNA;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ARTICLE; CELL POPULATION; CONTROLLED STUDY; DNA PACKAGING; FEMALE; GENE DOSAGE; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSECT CELL; LARGE SCALE PRODUCTION; MARKER GENE; MASTERWELL; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; REPRODUCIBILITY; STABLE TRANSFECTION; STANDARD; VIRUS CAPSID; VIRUS GENE; VIRUS PARTICLE; VIRUS STRAIN;

DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HELA CELLS; HUMANS; RECOMBINANT PROTEINS; TRANSFECTION; VIRAL PROTEINS; VIRUS ASSEMBLY;

EID: 84883020987     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2013.046     Document Type: Article

References (82)

1. Ali, R., Sarra, G.M., Stephens, C., et al. (2000). Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat. Genet. 25, 306-310. (Pubitemid 30437318)
2. Allay, J.A., Sleep, S., Long, S., et al. (2011). Good manufacturing practice production of self-complementary serotype 8 adenoassociated viral vector for a hemophilia B clinical trial. Hum. Gene Ther. 22, 595-604.
3. Allen, J.M., Debelak, D.J., Reynolds, T.C., and Miller, D. (1997). Identification and elimination of replication-competent adenoassociated virus (AAV) that can arise by nonhomologous recombination during AAV vector production. J. Virol. 71, 6816-6822. (Pubitemid 27355342)
4. Ayuso, E., Mingozzi, F., and Bosch, F. (2010). Production, purification and characterization of adeno-associated vectors. Curr. Gene Ther. 10, 423-436.
5. Bainbridge, J.W., Smith, A.J., Barker, S.S., et al. (2008). Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358, 2231-2239. (Pubitemid 351724452)
6. Blouin, V., Brument, N., Toublanc, E., et al. (2004). Improving rAAV production and purification: towards the definition of a scaleable process. J. Gene Med. 6, S223-S228. (Pubitemid 40228031)
7. Boccardo, E. (2010). HPV-mediated genome instability: at the roots of cervical carcinogenesis. Cytogenet. Genome Res. 128, 57-65.
8. Cao, L., During, M., and Xiao, W. (2002). Replication competent helper functions for recombinant AAV vector generation. Gene Ther. 9, 1199-1206.
9. Cao, M., Zyu, H., Bandyopadhyay, S., et al. (2011). HPV-16 E1, E2 and E6 each complement the Ad5 helper gene set, increasing rAAV2 and wt AAV2 production. Gene Ther. 19, 418-424.
10. Chadeuf, G., Favre, D., Tessier, J., et al. (2000). Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome. J. Gene Med. 2, 260-268.
11. Chadeuf, G., Ciron, C., Moullier, P., and Salvetti, A. (2005). Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. Mol. Ther. 12, 744-753. (Pubitemid 41350156)
12. Chang, L.S., Shi, Y., and Shenk, T. (1989). Adeno-associated virus p5 promoter contains an adenovirus E1A-inducible element and a binding site for the major late transcription factor. J. Virol. 8, 3479-3488. (Pubitemid 19181410)
13. Chen, T.R. (1988). Re-evaluation of HeLa, HeLa S3 and HEp-2 karyotypes. Cytogenet. Cell Genet. 48, 19-24.
14. Chusainow, J., Yang, Y.S., Yeo, J.H.M., et al. (2009). A study of monoclonal antibody-producing CHO cell lines: what makes a stable high producer? Biotechnol. Bioeng. 102, 1182-1196.
15. Cideciyan, A.V., Aleman, T.S., Boye, S.L., et al. (2008). Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc. Natl. Acad. Sci. USA 105, 15112-15117.
16. Cideciyan, A.V., Hauswirth, W.W., Aleman, T.S., et al. (2009a). Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum. Gene Ther. 20, 999-1004.
17. Cideciyan, A.V., Hauswirth, W.W., Aleman, T.S., et al. (2009b). Vision 1 year after gene therapy for Leber's congenital amaurosis. N. Engl. J. Med. 361, 725-727.
18. Clark, K.R., Voulgaropoulou, F., Fraley, D.M., and Johnson, P.R. (1995). Cell lines for the production of recombinant adenoassociated virus Hum. Gene Ther. 6, 1329-1341.
19. Fan, P., and Dong, J. (1997). Replication of rep-cap genes is essential for the high-efficiency production of recombinant AAV. Hum. Gene Ther. 8, 87-98. (Pubitemid 27075346)
20. Farris, K.D., and Pintel, D.J. (2008). Improved splicing of adenoassociated viral (AAV) capsid protein-supplying pre-mRNA's leads to increased recombinant AAV vector production. Hum. Gene Ther. 19, 1421-1427.
21. Farson, D., Harding, T.C., Tao, L., et al. (2004). Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors. J. Gene Med. 6, 1369-1381. (Pubitemid 40287708)
22. Gao, G.-P., Qu, G., Faust, L.Z., et al. (1998). High-titer adenoassociated viral vectors from a rep/cap cell line and hybrid shuttle virus. Hum. Gene Ther. 9, 2353-2362. (Pubitemid 28523984)
23. Gao, G.-P., Lu, F., Sanmiguel, J.C., et al. (2002). Rep/cap gene amplification and high-yield production of AAV in an A549 cell line expressing Rep/Cap. Mol. Ther. 5, 644-649. (Pubitemid 34546095)
24. Gao, G.-P., Wang, Q., Wang, L., et al. (2008). Inadvertent gene transfer of co-packaged rep and cap sequences during the production of AAV vector and its potential impact on vector performance. Mol. Ther. 16, S105-S106.
25. Graham, F.L., and Prevec, L. (1991). Manipulation of adenovirus vectors. In Gene Transfer and Protocol, Vol. 7. E.J. Murray, ed. (Humana Press, Clifton, NJ), pp. 109-128.
26. Grimm, D., Kern, A., Rittner, K., and Kleinschmidt, J.A. (1998). Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum. Gene Ther. 9, 2745-2760. (Pubitemid 29027018)
27. Grimm, D., Kern, A., Pawlita, M., et al. (1999). Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6, 1322-1330. (Pubitemid 29359028)
28. Hauck, B., Murphy, S.L., Smith, P.H., et al. (2009). Undetectable transcription of cap in a clinical AAV vector: Implications for preformed capsid in immune responses. Mol. Ther. 17, 144-152.
29. Henckaerts, E., Dutheil, N., Zeltner, N., et al. (2009). Site-specific integration of adeno-associated virus involves partial duplication of the target locus. Proc. Natl. Acad. Sci. USA 106, 7571-7576.
30. Herzog, R.W., Yang, E.Y., Couto, L.B., et al. (1999). Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX by adeno-associated viral vector. Nat. Med. 5, 56-63. (Pubitemid 29050999)
31. Horer, M., Weger, S., Butz, K., et al. (1995). Mutational analysis of adeno-associated virus Rep protein-mediated inhibition of heterologous and homologous promoters. J. Virol. 69, 5485-5496.
32. Howden, S.E., Voullaire, L., and Vadolas, J. (2008). The transient expression of mRNA coding for Rep protein from AAV facilitates targeted plasmid integration. J. Gene Med. 10, 42-50.
33. Inoue, N., and Russell, D.W. (1998). Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors. J. Virol. 72, 7024-7031. (Pubitemid 28377829)
34. Jenny, C., Toublanc, E., Danos, O., and Merten, O.-W. (2005). Evaluation of a serum-free medium for the production of rAAV-2 using HeLa derived producer cells. Cytotechnology 49, 11-23. (Pubitemid 43261103)
35. Jiang, Z., Huang, Y., and Sharfstein, S.T. (2006). Regulation of recombinant monoclonal antibody production in Chinese hamster ovary cells: a comparative study of gene copy number, mRNA level, and protein expression. Biotechnol. Prog. 22, 313-318. (Pubitemid 43221558)
36. Kaplitt, M.G., Leone, P., Samulski, R.J., et al. (1994). Long-term gene expression and phenotypic correction using adeno-associated virus ectors in the mammalian brain. Nat. Genet. 8, 148-154. (Pubitemid 24308362)
37. Kogure, K., Urabe, M., Mizukami, H., et al. (2001). Targeted integration of foreign DNA into a defined locus on chromosome 19 in K562 cells using AAV-derived components. Int. J. Hematol. 73, 469-475.
38. Kotin, R.M. (2011). Large-scale recombinant adeno-associated virus production. Hum. Mol. Genet. 20, R2-R6.
39. Labow, M.A., Hermonat, P.L., and Berns, K.I. (1986). Positive and negative autoregulation of the adeno-associated virus type 2 genome. J. Virol. 60, 251-258. (Pubitemid 16003167)
40. Li, J., Samulski, R.J., and Xiao, X. (1997). Role for highly regulated rep gene expression in adeno-associated virus vector production. J. Virol. 71, 5236-5243. (Pubitemid 27258196)
41. Linden, R.M., Winocour, E., and Berns, K.I. (1996). The recombination signals for adeno-associated virus site-specific integration. Proc. Natl. Acad. Sci. USA 93, 7966-7972. (Pubitemid 26277148)
42. Liu, X.L., Clark, K.R., and Johnson, P.R. (1999). Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus. Gene Ther. 6, 293-299. (Pubitemid 29089928)
43. Liu, X.L., Voulgaropoulou, F., Chen, R., et al. (2000). Selective rep-cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines. Mol. Ther. 2, 394-403.
44. Macville, M., Schrock, E., Padilla-Nash, H., et al. (1999). Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping. Cancer Res. 59, 141-150. (Pubitemid 29062970)
45. Maguire, A.M., Simonelli, F., Pierce, E.A., et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358, 2240-2248. (Pubitemid 351724453)
46. Maguire, A.M., High, K.A., Auricchio, A., et al. (2009). Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374, 1597-1605.
47. Mathews, L., Gray, J.T., Gallagher, M.R., and Snyder, R.O. (2002). Recombinant adeno-associated viral vector production using stable packaging and producer cell lines. Meth. Enz. 346, 393-413. (Pubitemid 41103150)
48. McCarty, D.M., Christensen, M., and Muzyczka, N. (1991). Sequences required for coordinate induction of adeno-associated virus p19 and p40 by Rep protein. J. Virol. 65, 2936-2945.
49. Meissner, J.D. (1999). Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines. J. Gen. Virol. 80, 1725-1733. (Pubitemid 29319864)
50. Meyers, C., Alam, S., Mane, M., and Hermonat, P.L. (2001). Altered biology of adeno-associated virus type 2 and human papillomavirus during dual infection of natural host tissue. Virology 287, 30-39. (Pubitemid 32778236)
51. Mouw,M.B., and Pintel, D.J. (2000). Adeno-associated virus RNA's appear in a temporal order and their splicing is stimulated during coinfection with adenovirus. J. Virol. 74, 9878-9888.
52. Muzyczka, N. (1992). Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 158, 97-129.
53. Nathwani, A.C., Tuddenham, E.G., Rangarajan, S., et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357-2365.
54. Nony, P., Tessier, J., Chadeuf, G., et al. (2001). Novel cis-acting replication element in the adeno-associated virus type 2 genome is involved in amplification of integrated rep-cap sequences. J. Virol. 75, 9991-9994. (Pubitemid 32900135)
55. Ogston, P., Raj, K., and Beard, P. (2000). Productive replication of adeno-associated virus can occur in human papillomavirus type 16 (HPV-16) episome-containing keratinocytes and is augmented by the HPV-16 E2 protein. J. Virol. 8, 3494-3504. (Pubitemid 30180291)
56. Pendse, T.J., Karkare, S., and Bailey, J.E. (1992). Effect of cloned gene dosage on cell growth and hepatitis B surface antigen synthesis and secretion in recombinant CHO cells. Biotechnol. Bioeng. 40, 119-129.
57. Pereira, D.J., McCarty, D.M., and Muzyczka, N. (1997). Adenoassociated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection. J. Virol. 71, 1079-1088. (Pubitemid 27030279)
58. Philpott, N., Gomos, J., and Falck-Pedersen, E. (2004). Transgene expression after Rep-mediated site-specific integration into chromosome19. Hum. Gene Ther. 15, 47-61. (Pubitemid 38147188)
59. Pieroni, L., Fipaldini, C., Monciotti, A., et al. (1998). Targeted integration of adeno-associated virus-derived plasmids in transfected human cells. Virology 249, 249-259. (Pubitemid 28460878)
60. Popescu, N.C., DiPaolo, J.A., and Amsbaugh, S.C. (1987). Integration sites of human papollomavirus 18 DNA sequences on HeLa cell chromosomes. Cytogenet. Cell Genet. 44, 58-62. (Pubitemid 17037174)
61. Qiao, C.,Wang, B., Zhu, X., et al. (2002). A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines. J. Virol. 76, 13015-13027. (Pubitemid 35386985)
62. Simonelli, F., Maguire, A.M., Testa, F., et al. (2010). Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther. 18, 643-650.
63. Snyder, R.O., Miao, C., Meuse, L., et al. (1999). Correction of hemophila B in canine and murine models using recombinant adeno-associated viral vectors. Nat. Med. 5, 64-70. (Pubitemid 29051000)
64. Surosky, R.T., Urabe, M., Godwin, S., et al. (1997). Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome. J. Virol. 71, 7951-7959. (Pubitemid 27391747)
65. Tamayose, K., Hirai, Y., and Shimada, T. (1996). A new strategy for large-scale preparation of high-titer recombinant adenoassociated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. Hum. Gene Ther. 7, 507-513. (Pubitemid 26079061)
66. Tatalick, L.M., Gerard, C.J., Takeya, R., et al. (2005). Safety characterization of HeLa-based cell substrates used in the manufacture of a recombinant adeno-associated virus-HIV vaccine. Vaccine 23, 2628-2638. (Pubitemid 40380808)
67. Tessier, J., Chadeuf, G., Nony, P., et al. (2001). Characterization of adenovirus-induced inverted terminal repeat-independent amplification of integrated adeno-associated virus rep-cap sequences. J. Virol. 75, 375-383.
68. Thorne, B.A., Takeya, R.K., and Peluso, R.W. (2009). Manufacturing recombinant adeno-associated viral vectors from producer cell clones. Hum. Gene Ther. 20, 707-714.
69. Toublanc, E., Benraiss, A., Bonnin, D., et al. (2004). Identification of a replication-defective herpes simplex virus for recombinant adeno-associated virus type 2 (rAAV2) particle assembly using stable producer cell lines. J. Gene Med. 6, 555-564. (Pubitemid 40228071)
70. Tsunoda, H., Hayakawa, T., Sakuragawa, N., and Koyama, H. (2000). Site-specific integration of adeno-associated virusbased plasmid vectors in lipofected HeLa cells. Virology 68, 391-401. (Pubitemid 30159988)
71. Vincent, K.A., Piraino, S.T., and Wadsworth, S.C. (1997). Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products. J. Virol. 71, 1897-1905. (Pubitemid 27078567)
72. Wang, X.S., Khuntirat, B., Qing, K., et al. (1998). Characterization of wild-type adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their elimination. J. Virol. 2, 5472-5480. (Pubitemid 28283329)
73. Ward, P., Elias, P., and Linden, R.M. (2003). Rescue of the adenoassociated virus genome from a plasmid vector: evidence for rescue by replication. J. Virol. 77, 11480-11490. (Pubitemid 37271646)
74. Weger, S., Wistuba, A., Grimm, D., and Kleinschmidt, J.A. (1997). Control of adeno-associated virus type 2 cap gene expression: relative influence of helper virus, terminal repeats, and rep proteins. J. Virol. 71, 8437-8447. (Pubitemid 27446424)
75. Wistuba, A., Weger, S., Kern, A., and Kleinschmidt, J.A. (1995). Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins. J. Virol. 9, 5311-5319.
76. Wright, J.F. (2009). Transient transfection methods for clinical adeno-associated viral vector production. Hum. Gene Ther. 20, 698-706.
77. Yang, Q., Chen, F., and Trempe, J.P. (1994). Characterization of cell lines that inducibly express the adeno-associated virus Rep proteins. J. Virol. 8, 4847-4856.
78. Yew, N., Przybylska, M., Ziegler, R.J., et al. (2001). High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. Mol. Ther. 4, 75-82. (Pubitemid 32684705)
79. Yla-Herttuala, S. (2012). Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol. Ther. 20, 1831-1832.
80. You, H., Liu, Y., Prasad, C.K., et al. (2006). Multiple human papillomavirus genes affect the adeno-associated virus life cycle. Virology 2, 532-540. (Pubitemid 43049637)
81. Yuan, Z., Qiao, C., Hu, P., et al. (2011). A versatile AAV producer cell line method for scalable vector production of different serotypes. Hum. Gene Ther. 22, 613-624.
82. Zeltner, N., Kohlbrenner, E., Clement, N., et al. (2010). Near perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors. Gene Ther. 17, 872-879.